Albany NY, United States: Methemoglobinemia is a condition when more than 1% of hemoglobin in the blood gets oxidized to methamoglobin, which is an abnormal form of hemoglobin unable to bind the oxygen molecules.
Albany NY, United States: Methemoglobinemia is a condition when more than 1% of hemoglobin in the blood gets oxidized to methamoglobin, which is an abnormal form of hemoglobin unable to bind the oxygen molecules. The iron atom gets oxidized from the ferrous state (Fe2+) to the ferric state (Fe3+), losing an electron to an oxidant. This results in anemia, cyanosis, dizziness, fatigue, headache, dyspnea on exertion, and tachycardia. When the levels of methamoglobin in the blood exceeds 50%, it can cause dysrhythmias, hypotension, acidosis, coma, and death. The two common causes of methemoglobinemia are genetic and acquired. Acquired methemoglobinemia is caused by exposure to certain oxidizing substances that lead to the conversion of hemoglobin to methemoglobin. For instance, anilines, dyes, nitrates and nitrites, and medications including lidocaine, prilocaine, benzocaine, chloroquine, and dapsone. Rise in incidence of acquired methemoglobinemia owing to increase in use of local anesthetics, surge in use of silver nitrates for the treatment of wounds, eating nitrate rich vegetables, and growing awareness about the available treatments are the factors expected to drive the global acquired methemoglobinemia treatment market during the forecast period. High cost of blood products and lack of trained physicians in rural areas are the factors likely to restrain the global acquired methemoglobinemia treatment market.
Read Report Overview - https://www.transparencymarketresearch.com/acquired-methemoglobinemia-treatment-market.html
The global acquired methemoglobinemia treatment market can be segmented based on type of treatment, end-user, and region. In terms of type of treatment, the global market can be categorized into drug therapy, blood transfusion therapy, and oxygen therapy. The drug therapy segment can be classified into methylene blue, dextrose, and ascorbic acid treatment. The methylene blue sub-segment is anticipated to dominate the drug therapy segment during the forecast period due to its positive performance to reverse the condition. Based on end-user, the global acquired methemoglobinemia treatment market can be divided into hospitals, clinics, and ambulatory care centers. The hospitals segment is expected to account for the major market share during the forecast period, attributed to patient preference for hospitals to treat such emergency cases and availability of equipment at hospitals such as oxygen therapy and blood transfusion devices. The clinics segment is expected to expand at the highest CAGR from 2018 to 2026.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=44940
Geographically, the global acquired methemoglobinemia treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the market due to availability of advanced therapeutic options to treat the disease, high health care awareness among the population, and high health care expenditure. The market in Asia Pacific is expected to expand at the highest CAGR due to increasing use of local anesthetics, rise in health care awareness, and surge in health care spending. High use of antibiotics such as dapsone and chloroquine to treat infections is responsible for rise in incidence of acquired methemoglobinemia in the region. Moreover, poor sanitation in Middle East & Africa, Latin America, and some parts of the Asia also contribute towards the increasing incidence of acquired methemoglobinemia in these regions. This is expected to further drive the growth of the global acquired methemoglobinemia treatment market during the forecast period.
Request for Analysis of COVID-19 Impact on Acquired Methemoglobinemia Treatment Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=44940
Key players operating in the global acquired methemoglobinemia treatment market include GlaxoSmithKline plc, Mylan N.V., American Regent, Inc., Teligent, Inc., Provepharm Life Solutions, McGuff Company, Inc., Abundance Naturally Limited, Kedrion Biopharma, Inc., and Octapharma.
Pre Book Acquired Methemoglobinemia Treatment Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=44940<ype=S
This intelligence report by TMR is the outcome of intense study and rigorous assessment of various dynamics shaping the growth of the market. TMR nurtures a close-knit team of analysts, strategists, and industry experts who offer clients tools, methodologies, and frameworks to make smarter decisions. Our objective, insights, and actionable analytics provide CXOs and executives to advance their mission-critical priorities with confidence.
More Trending Reports by Transparency Market Research:
Vascular Grafts Market Vascular diseases have high worldwide mortality, propelling advances in endovascular surgeries. Developing effective and long-term revascularization solutions has gathered immense attention among healthcare providers. Autologous arteries or veins as well as synthetic grafts have gained acceptance in the vascular grafts market. A key aim is to improve patency rates in such procedures. In this light, tissue-engineered vascular grafts are attracting attention and research interest among industry players.
Virus Filtration Market The demand for virus removal during monoclonal antibodies (MAbs) production processes has spurred the prospects in the virus filtration market. Over the past few years, remarkable technological advances have been made in mAb downstream processes, with new mAb platforms seeing good prospect. The growing demand for high-concentration monoclonal antibody solutions in lifesciences industries has nudged manufacturers of virus filtration to focus on numerous performance parameters.
Meningococcal Vaccines Market Rising awareness regarding the vaccines due to awareness campaigns and education has resulted in growth in demand rate. The campaigns and awareness programs are particularly being driven by vaccine manufacturing companies, government bodies, and non-profit organizations. Large number of people are getting immunized against bacterial meningitis.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/